Effectiveness of Inactivated Influenza Vaccine for Prevention of Otitis Media in Children

Ozgur, Senem Konuk; Beyazova, Ufuk; Kemaloğlu, Yusuf Kemal; Maral, İşıl; Sahın, Figen; Çamurdan, Aysu Duyan; Kızıl, Yusuf; Dinç, Erdem; Tüzün, Hakan

doi:10.1097/01.inf.0000217370.83948.51

Cited by 58 publications

(25 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ozgur et al 23 showed that there was a 50.9% decrease in the incidence of AOM in a groups of children aged between 6 months and 5 years, compared to controls; this study also demonstrated a 26.7% decrease in the total number of cases of otitis media with effusion in a 6-month follow-up period.…”

Section: C) the Inactivated Influenza Virus Vaccinesupporting

confidence: 50%

O papel de novas vacinas na prevenção da otite média

Felix¹,

Gomes²,

Cabral³

et al. 2008

Rev. Bras. Otorrinolaringol.

View full text Add to dashboard Cite

A Otite Média é uma das doenças infecciosas mais comuns da infância e a diminuição de sua incidência levaria a um grande impacto econômico e social para o mundo. Como uma das formas de prevenção temos as vacinas. As duas vacinas escolhidas para esta revisão são as vacinas antipneumocócica e antiinfluenza. Esta revisão da literatura procurou mostrar os resultados dos principais estudos sobre essas vacinas e seu papel na prevenção da otite média. A vacina antipneumocócica polissacarídea 23-valente não alterou a incidência de otite média pela ineficácia para menores de 2 anos, grupo de maior incidência dessa enfermidade. A vacina antipneumocócica heptavalente, apesar de não provocar grande queda na incidência geral de otite média, mudou o perfil de seus microorganismos causadores, diminuindo os episódios de otite média com efusão e recorrente e aumentando as otites causadas por H. influenza, M. catarrhalis e sorotipos de pneumococo ausentes da vacina heptavalente. A vacina antiinfluenza com vírus inativado mostrou-se efetiva na redução da otite média aguda nos períodos de maior incidência desse vírus. Os otorrinolaringologistas devem estar cientes do papel dessas novas vacinas já disponíveis no Brasil e seu impacto na redução da otite média, para saber orientar adequadamente os seus pacientes.

show abstract

Section: C) the Inactivated Influenza Virus Vaccinesupporting

confidence: 50%

O papel de novas vacinas na prevenção da otite média

Felix¹,

Gomes²,

Cabral³

et al. 2008

Rev. Bras. Otorrinolaringol.

View full text Add to dashboard Cite

show abstract

“…62 Vaccine efficacy of 56% against influenza illness was documented among healthy children 3 to 9 years of age, 49 and another study determined vaccine efficacy against influenza type B and A infections of 22% to 54% and 60% to 78% among children with asthma 2 to 6 years of age and 7 to 14 years of age, respectively. 79 TIV has also been found to considerably decrease the incidence of influenza-attributable otitis media among young children, [80][81][82] although another study contradicts this finding. 63 Results have also shown the efficacy and effectiveness of LAIV.…”

Section: Immunogenicitycontrasting

confidence: 43%

Prevention of Influenza: Recommendations for Influenza Immunization of Children, 2007–2008

Bocchini¹,

Bernstein²,

Bradley³

et al. 2008

Pediatrics

View full text Add to dashboard Cite

The American Academy of Pediatrics recommends annual influenza immunization for all children with high-risk conditions who are 6 months of age and older, for all healthy children ages 6 through 59 months, for all household contacts and out-of-home caregivers of children with high-risk conditions and of healthy children younger than 5 years, and for all health care professionals. To more fully protect against the morbidity and mortality of influenza, increased efforts are needed to identify and immunize all children at high risk and all healthy children ages 6 through 59 months and to inform their parents when annual immunizations are due. Previously unimmunized children who are at least 6 months of age but younger than 9 years should receive 2 doses of influenza vaccine, given 1 month apart, beginning as soon as possible on the basis of local availability during the influenza season. If children in this cohort received only 1 dose for the first time in the previous season, it is recommended that 2 doses be administered in the current season. This recommendation applies only to the influenza season that follows the first year that a child younger than 9 years receives influenza vaccine. A child who then also fails to receive 2 doses the next year should be given only 1 dose per year from that point on. Influenza vaccine should also continue to be offered throughout the influenza season, even after influenza activity has been documented in a community. On the basis of global surveillance of circulating virus strains, the influenza vaccine may change from year to year; indeed, 1 of the 3 strains in the 2007–2008 vaccine is different from the previous year's vaccine. All health care professionals, influenza campaign organizers, and public health agencies should develop plans for expanding outreach and infrastructure to immunize all children for whom influenza vaccine is recommended. Appropriate prioritization of administering influenza vaccine will also be necessary when vaccine supplies are delayed or limited. Because the influenza season often extends into March, immunization against influenza is recommended to continue through late winter and early spring. Lastly, it is recommended that for the 2007–2008 season, and likely beyond, health care professionals do not prescribe amantadine or rimantadine for influenza treatment or chemoprophylaxis, because widespread resistance to these antiviral medications now exists among influenza A viral strains. However, oseltamivir and zanamivir can be prescribed for treatment or chemoprophylaxis, because influenza A and B strains remain susceptible.

show abstract

“…In one study conducted in Turkey, influenza vaccination significantly reduced acute otitis media in children by 50.9% compared to unvaccinated controls and by inference antibiotic use in the vaccinated children. 34 A study conducted in Canada demonstrated convincingly that influenza associated antibiotic prescriptions declined by ∼64% after introduction of universal influenza vaccination in Ontario compared to other Canadian provinces that limited the use of influenza vaccines to populations most at risk for disease. 35 The second mechanism by which viral vaccines can reduce AMR is by prevention of inappropriate antibiotic prescriptions for respiratory tract infections caused by viral pathogens.…”

Section: Impact Of Viral Vaccines On Amrmentioning

confidence: 99%

The role of vaccines in fighting antimicrobial resistance (AMR)

Jansen

Anderson

2018

Human Vaccines & Immunotherapeutics

107

View full text Add to dashboard Cite

The problem of antimicrobial resistance (AMR) and the associated morbidity and mortality due to antibiotic resistant bacterial pathogens is not new. However, AMR has been increasing at an alarming rate with appearances of diseases caused by bacteria exhibiting resistance to not just one but multiple classes of antibiotics. The World Health Organization (WHO) supported by governments, health ministries and health agencies has formulated global action plans to combat the rise in AMR, supporting a number of proven initiatives such as antimicrobial stewardship, investments in development of new classes of antibiotics, and educational programs designed to eliminate inappropriate antibiotic use. Vaccines as tools to reduce AMR have historically been under-recognized, yet the positive effect in reducing AMR has been well established. For example Haemophilus influenzae type B (Hib) as well as Streptococcus pneumoniae (pneumococcal) conjugate vaccines have impressive track records in not only preventing life threatening diseases caused by these bacteria, but also reducing antibiotic use and AMR. This paper will describe the drivers of antibiotic use and subsequent development of AMR; it will make the case how existing vaccines are already participating in combatting AMR, describe future prospects for the role of new vaccines in development to reduce AMR, and highlight challenges associated with future vaccine development to combat AMR.

show abstract

Effectiveness of Inactivated Influenza Vaccine for Prevention of Otitis Media in Children

Abstract: Influenza vaccine is effective in reducing AOM and OME episodes in 6- to 60-month-old day care children, especially during influenza season.

Cited by 58 publications

References 18 publications

O papel de novas vacinas na prevenção da otite média

O papel de novas vacinas na prevenção da otite média

Prevention of Influenza: Recommendations for Influenza Immunization of Children, 2007–2008

The role of vaccines in fighting antimicrobial resistance (AMR)

Contact Info

Product

Resources

About